Case Studies
University College Cork – National University of Ireland, Cork (UCC)
Sustainability: Perfect condition of aliquots and reuseable packaging
"Overall, I'm very happy with my purchase from Evidentic, and I would highly recommend them to anyone looking for high-quality products with sustainable packaging."
Tara Foley
Senior Technical Officer | Dept of Anatomy and Neuroscience
National Institute for Bioprocessing Research and Training (NIBRT)
Quality and Service: Fast and easy ordering processes meet the needs in highly work-intense phase
“We are thankful and more than happy to work with the Evidentic. Not only are the drug aliquots in the best quality and satisfy our requests to the full extent, but also can we absolutely rely on the whole Evidentic team."
Sara Carillo
Bioanalytical Research Lead, National Institute for Bioprocessing Research and Training (NIBRT)/Ireland
ICNAS
Academia: Optimize and validate research protocols with mAb drug aliquots
“Evidentic was the only source that offered small aliquots of original therapeutic mAbs at an affordable price range. The aliquots came in an easy-to-use-and-store format that was apt for my research purpose.”
Ivanna Hrynchak
PhD Student, ICNAS, Universidade d Coimbra, Portugal
ExcellGene
Biosimilars: Reference Drug Aliquots for Faster Selection and Development of CHO-based Production Processes
“Evidentic drug aliquots have helped us speed up our antibody characterization assays and selection of clonal cell lines. An easy and reliable source!”
Prof. (emeritus) Dr. Florian Wurm
Chief Scientific Officer and Founder, ExcellGene SA
UGA Biopharma GmbH
Aliquots: A New Solution to the Batch Variability Problem
“Evidentic drug aliquots have significantly reduced our development cycle time and strengthened our ability to do detailed [protein] characterization.”
Dr Stephan Schultz
Team Leader of Analytics/DSP at UGA Biopharma GmbH
Deka BioSciences
Reference Drug Aliquots: The right control for Assays
“Evidentic’s Drug aliquots helped us to ascertain the efficacy of our novel molecule [in comparison to commercial therapeutic antibody] which supported our fundraising efforts.”
Pavel Khrimian
Co-founder & CBO at Deka Biosciences Inc